Results 201 to 210 of about 634,741 (343)

Dynamic nanoscale architecture of synaptic vesicle fusion in mouse hippocampal neurons. [PDF]

Nat Commun
Kroll J, Kravčenko U, Sadeghi M, Diebolder CA, Ivanov L, Lubas M, Sprink T, Schacherl M, Kudryashev M, Rosenmund C.   +9 more
europepmc   +1 more source

Depressive symptoms as independent correlates of epilepsy‐related cognitive burden

Epilepsia, EarlyView.
Abstract Objective This study was undertaken to assess the relationship between the severity of depression and anxiety symptoms and epilepsy‐related variables and cognitive burden in people with epilepsy (PwE), as assessed using EpiTrack. Methods We prospectively enrolled a cohort of PwE who underwent EpiTrack and evaluation by Generalized Anxiety ...
Biagio Maria Sancetta, Giuli Lippa, Marianna Nesta, Lorenzo Ricci, Simona Paola Carbone, Lorenzo Veronese, Giulia Conti, Marco Sferruzzi, Vincenzo Di Lazzaro, Mario Tombini, Giovanni Assenza   +10 more
wiley   +1 more source

"Kiss-shrink-run" unifies mechanisms for synaptic vesicle exocytosis and hyperfast recycling. [PDF]

Science
Tao CL, Tian CL, Liu YT, Lu ZH, Qi L, Li XW, Li C, Shen X, Gu ML, Huang WL, Liu S, Yang LQ, Liao Z, Ma X, Wu J, Sun J, Wang P, Lau PM, Zhou ZH, Bi GQ.   +19 more
europepmc   +1 more source

Synucleins Regulate the Kinetics of Synaptic Vesicle Endocytosis

Journal of Neuroscience, 2014
K. Vargas, S. Makani, T. Davis, C. Westphal, P. Castillo, S. Chandra   +5 more
semanticscholar   +1 more source

SV2A expression in blood cells as a possible biomarker candidate for levetiracetam treatment response

Epilepsia, EarlyView.
Abstract Objective This study was undertaken to evaluate whether synaptic vesicle protein 2A (SV2A) expression on peripheral immune cells predicts treatment response to levetiracetam in epilepsy. Methods High‐dimensional flow cytometry was used to prospectively assess SV2A expression on immune cells from levetiracetam responders, nonresponders, and ...
Johannes Lang, Mathias Linnerbauer, Jeanne Cuny, Veit Rothhammer, Hajo Hamer   +4 more
wiley   +1 more source

Synaptic Vesicle Recycling at the Developing Presynapse. [PDF]

J Neurochem
Kim N, Cousin MA.
europepmc   +1 more source

Long‐lasting remodeling of astrocytes in an Scna1+/− mouse model of Dravet syndrome

Epilepsia, EarlyView.
Abstract Objective Dravet syndrome (DS) is a prototypical developmental and epileptic encephalopathy caused by mutations in the SCN1A gene, leading to loss of function of the voltage‐gated sodium channel Naᵥ1.1. The latter causes early onset drug‐resistant seizures and enduring cognitive and behavioral deficits.
Athénaïs Genin, Alicia Janvier, Tristan Moujellil‐Legagneur, Marine Blaquière, Alexis Chaussy, Romane Privé, Fabrice Duprat, Massimo Mantegazza, Etienne Audinat, Nicola Marchi, Noémie Cresto   +10 more
wiley   +1 more source

Phosphorylation of presynaptic PLPPR3 controls synaptic vesicle release. [PDF]

iScience
Kroon C, Bareesel S, Perez GA, Nagy-Herczeg D, Ranti D, Syropoulou V, Coveney S, Kirchner M, Gimber N, Bintig W, Brosig A, Braune G, Textoris-Taube K, Zolnik TA, Mertins P, Schmoranzer J, Milovanovic D, Leondaritis G, Eickholt BJ.   +18 more
europepmc   +1 more source

Merits and Limitations of Vesicle Pool Models in View of Heterogeneous Populations of Synaptic Vesicles.

Neuron, 2015
E. Neher
semanticscholar   +1 more source

Ranking of antiseizure medications in a panel of focal seizure models predicts their comparative efficacy in clinical add‐on trials in drug‐resistant focal epilepsy

Epilepsia, EarlyView.
Abstract Objective Most antiseizure medications (ASMs) have been discovered by testing in animal models, which are generally thought to predict antiseizure activity in patients. However, it is not known whether any of these models (or a combination of models) can predict whether a novel ASM exhibits higher clinical efficacy in focal drug‐resistant ...
Wolfgang Löscher, Pavel Klein
wiley   +1 more source